Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163994 | 0.86 | SNCA (0.37) | EGFRSNCATSHRP4HB | |
| SCHEMBL2666218 | 0.85 | EGFR (0.40) | EGFRSNCACA2CA12CA4 | |
| SCHEMBL14769310 | 0.85 | ABAT (0.38) | SNCACA2CA12CA4CA6 | |
| SCHEMBL10264740 | 0.85 | CA2 (0.36) | EGFRSNCACA2CA12CA4 | |
| SCHEMBL6224881 | 0.81 | TAAR1 (0.47) | SNCATSHRRECQLKDM4ESLC6A2 | |
| SCHEMBL29171915 | 0.81 | CNR1 (0.46) | SNCACA2 | |
| SCHEMBL6705605 | 0.81 | TAAR1 (0.48) | SNCARECQLKDM4ESLC6A2SLC6A3 | |
| SCHEMBL16951823 | 0.81 | CNR2 (0.37) | EGFRSNCACA2SLC6A2SLC6A4 | |
| SCHEMBL29586802 | 0.81 | EGFR (0.39) | EGFRSNCACA2CA12CA4 | |
| SCHEMBL5936407 | 0.81 | EGFR (0.39) | EGFRSNCACA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-117050126-A | Novel preparation method of key isomer of tolagliflozin | 南京华威医药科技集团有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116655718-A | Togliflozin five-membered ring impurity and preparation method thereof | 南京华威医药科技集团有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220298179-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | SAINT JOSEPH'S UNIVERSITY | 2022-09-22 | — | — | US | disclosed |
| US-11427603-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | UNIVERSITY OF THE SCIENCES (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| US-6509507-B2 | Reacting a 6-membered aromatic ring with 1,4- position ester or benzylic OH groups with a second aromatic in a palladium catalyzed cross-coupling; electroluminescence | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2003-01-21 | — | — | US | disclosed |
| US-6458909-B1 | SOLID-STATE LIGHT SOURCES FOR A SERIES OF APPLICATIONS, PREDOMINANTLY IN THE FIELD OF DISPLAY ELEMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-20020087030-A1 | Polymerizable biaryls, process for their preparation and their use | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | US | disclosed |
| EP-0944569-B1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | CELANESE VENTURES GMBH (DE) | 2002-04-10 | — | — | EP | disclosed |
| EP-0944663-B1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | CELANESE VENTURES GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6323373-B1 | USED TO OBTAIN POLYMERS WHICH ARE USED AS ELECTROLUMINESCENCE MATERIALS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-0944663-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | Celanese Ventures GmbH (DE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0944569-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998027136-A1 | ARYL-SUBSTITUTED POLY(p-ARYLENE VINYLENES), METHOD FOR THE PRODUCTION AND USE THEREOF IN ELECTROLUMINESCENT COMPONENTS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025874-A1 | POLYMERIZABLE BIARYLS, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | TXN2, ABCB7, TXN | EGFR 4674/4885SNCA 1139/4885CA2 1060/4885 |
| US-11427603-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | ABCB7, TXN2, PRDX3 | EGFR 4655/4885SNCA 1398/4885CA2 1202/4885 |
| US-20220298179-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | TXN2, ABCB7, TXN | EGFR 4674/4885SNCA 1139/4885CA2 1060/4885 |
| US-20020087030-A1 | Polymerizable biaryls, process for their preparation and their use | PAH, TYR, PAICS | EGFR 1174/4885SNCA 150/4885CA2 4541/4885 |
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | EGFR 4818/4885SNCA 1611/4885CA2 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.